Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
20.13
-1.87 (-8.50%)
Apr 1, 2025, 4:00 PM EDT - Market closed

Edgewise Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Net Income
-133.81-100.16-67.64-42.81-17.12
Upgrade
Depreciation & Amortization
2.291.730.540.270.19
Upgrade
Loss (Gain) From Sale of Investments
-12.55-9.52-0.54--
Upgrade
Stock-Based Compensation
24.7117.5610.924.40.35
Upgrade
Change in Accounts Payable
1.74-0.090.052.650.52
Upgrade
Change in Other Net Operating Assets
8.59-1.474.041.981.43
Upgrade
Operating Cash Flow
-109.03-91.95-52.64-33.51-14.63
Upgrade
Capital Expenditures
-1.31-5.75-5.55-0.67-0.2
Upgrade
Investment in Securities
-183.34108.63-65.03-241.56-24.18
Upgrade
Investing Cash Flow
-184.66102.89-70.58-242.23-24.38
Upgrade
Issuance of Common Stock
249.5253.33129.89186.510.2
Upgrade
Other Financing Activities
-0.26-0.17-0.25-0.12-
Upgrade
Financing Cash Flow
249.2553.17129.64186.38120.28
Upgrade
Net Cash Flow
-44.4364.16.43-89.3581.26
Upgrade
Free Cash Flow
-110.34-97.69-58.18-34.18-14.84
Upgrade
Free Cash Flow Per Share
-1.19-1.53-1.09-0.91-20.08
Upgrade
Levered Free Cash Flow
-63.22-61.66-35.48-19.26-7.36
Upgrade
Unlevered Free Cash Flow
-63.22-61.66-35.48-19.26-7.36
Upgrade
Change in Net Working Capital
-10.363.74-3.39-3.75-3.05
Upgrade
Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q